DOCSLIB.ORG

Oxiconazole Nitrate (BANM, USAN, Rinnm) Tral.: Kenacomb; Otocomb Otic; Austria: Mycostatin V; Mycostatin- Fungichromin; Lagosin; Pentamicina

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oxiconazole Nitrate (BANM, USAN, Rinnm) Tral.: Kenacomb; Otocomb Otic; Austria: Mycostatin V; Mycostatin- Fungichromin; Lagosin; Pentamicina 544 Antifungals Port.: Mycostatin; S.Afr.: Candacide; Canstat; Mycostatin; Nystacid; Singa- Preparations Profile pore: Mycostatin†; Spain: Mycostatin; Swed.: Mycostatin; Switz.: Mycos- Parconazole is an antifungal that has been used as the hydrochlo- tatine; Thai.: Lystin†; Mycostatin; Turk.: Fungostatin; Mikostatin; UAE: Proprietary Preparations (details are given in Part 3) ride in the treatment of gastrointestinal candidiasis in veterinary Mikostat; UK: Nystamont†; Nystan; USA: Mycostatin; Nilstat; Nystop; Pedi- Dri; Venez.: Micostatin; Nistafesa†; Romalina†. Austria: Afongan; Fr.: Fongamil; Fongarex; Gr.: Fongamil; Hung.: Mikogal; medicine. Mex.: Afongan; Port.: Afongan†; Fongamil; Rus.: Mikogal (Микогал). Multi-ingredient: Arg.: Bacticort Complex; Bexon; Biotaer Gamma†; Bi- otaer Nebulizable; Dermadex NN; Farm-X Duo; Fasigyn Nistatina; Flagys- tatin; Kenacomb; Linfol; Min O; Naxo TV; Neocolpoben†; Nistinol; O-Biol; Pentamycin O-Biol P; Pelvicillin NF; Polygynax; Terra-Cortril Nistatina†; Tratomax; Aus- Oxiconazole Nitrate (BANM, USAN, rINNM) tral.: Kenacomb; Otocomb Otic; Austria: Mycostatin V; Mycostatin- Fungichromin; Lagosin; Pentamicina. Zinkoxid; Topsym polyvalent; Belg.: Eoline†; Mycolog; Polygynax†; Braz.: Nitrato de oxiconazol; Oxiconazole, Nitrate d’; Oxiconazoli Ni- Benzevit; Bio-Vagin; Colpagex N; Colpatrin; Colpist; Colpistar; Colpistatin; Пентамицин tras; Ro-13-8996; Ro-13-8996/001; Ro-13-8996/000 (oxicona- Colpolase; Dermodex; Dermokin; Donnagel; Flagyl Nistatina; Fungimax; Gi- C35H58O12 = 670.8. nec†; Ginestatin; Gynax-N; Londerm-N; Minegyl C/Nistatina†; Mud; Nax- zole); SGD-301-76; ST-813. 2′,4′-Dichloro-2-imidazol-1-ylace- CAS — 6834-98-6. ogin Composto; Neolon-D; Nistazol†; Omcilon A M; Onciplus; Oxyderme; tophenone (Z)-O-(2,4-dichlorobenzyl)oxime mononitrate. Poliginax; Tricolpex; Tricomax; Trivagel N; Vagi Biotic; Vagimax; Vagitrin-N; ATC — G01AA11. Canad.: Flagystatin; Kenacomb†; ratio-Triacomb; Triacomb†; Viaderm-KC; Оксиконазола Нитрат ATC Vet — QG01AA11. Chile: Multilind; Naxogin Compositum; Naxogin Dos†; Nistaglos; Cz.: Macmiror Complex; Polygynax; Denm.: Kenalog Comp med Mycostatin; C18H13Cl4N3O,HNO3 = 492.1. Fin.: Flagyl Comp; Fr.: Auricularum; Mycolog†; Polygynax; Polygynax Virgo; OH OH OH OH OH OH Tergynan; Ger.: Aureomycin N†; Candio-Hermal Plus; Halog Tri†; Jellin CAS — 64211-45-6 (oxiconazole); 64211-46-7 (oxicona- polyvalent†; Lokalison-antimikrobiell Creme N; Moronal V; Multilind; Myko- zole nitrate). HC proct sine; Mykundex Heilsalbe; Nystaderm comp; Nystalocal; Penanyst; ATC — D01AC11; G01AF17. H Polygynax†; Topsym polyvalent; Volonimat Plus N; Gr.: Kenacomb; Hong OH Kong: Kenacomb; Macmiror Complex; Polygynax; Triacomb; India: Kena- ATC Vet — QD01AC11; QG01AF17. O O HO comb; Indon.: Fasigyn-Nystatin; Fladystin; Flagystatin; Gynoxa; Myco-Z; Naxogin Complex; New Kenacomb; Trichostatic; Vagistin; Irl.: Kenacomb; HC OH Nystaform-HC†; Nystaform†; Timodine; Tinaderm-M; Israel: Auricularum; OH CH Dermacombin; Kenacomb†; Ital.: Assocort; Fasigin N; Macmiror Complex; N Malaysia: Kenacomb; Mex.: Acenil; Bidrozil; Decadron con Nistatina; Dermalog-C; Flagystatin V; Kenacomb; Macmiror Complex V; Metrofur; Mi- Profile costatin Baby; Novageon; Nysmosons-V; Promibasol-Plus; Vagitrol-V; N Pentamycin is a polyene antifungal antibiotic obtained from Neth.: Mycolog; NZ: Kenacomb; Viaderm-KC; Philipp.: Dermovate-NN; Streptomyces pentaticus. It has been used in the treatment of vag- Flagystatin; Kenacomb; Lidex NGN; Pol.: Macmiror Complex; Triacomb; inal candidiasis and for the protozoal infection trichomoniasis. Port.: Dafnegil; Dermovate-NN†; Kenacomb; Rus.: Macmiror Complex Cl Cl (Макмирор Комплекс); Polygynax (Полижинакс); Tergynan (Тержинан); S.Afr.: Duoderm†; Hiconcil-NS; Kenacomb; Riostatin; Tetrex-F; Singa- O N pore: Flagystatin; Kenacomb†; Polygynax; Spain: Interderm; Intradermo Cl Cl Cort Ant Fung†; Milrosina Nistatina; Positon; Swed.: Kenacombin Novum; Switz.: Dermovate-NN; Multilind; Mycolog N; Mycolog†; Nystacortone†; Posaconazole (BAN, USAN, rINN) Nystalocal; Topsym polyvalent; Thai.: Dermacombin; Gynecon; Gynecon- (oxiconazole) T; Gynoco; Gynova; Gyracon; Kenacomb; Nystin; Quinradon-N; Vagicin; Posaconazol; Posaconazolum; Sch-56592. 4-{p-[4-(p-{[(3R,5R)- UAE: Mikostat Baby Ointment; Panderm; UK: Dermovate-NN; Grego- 5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylme- derm†; Nystaform; Nystaform-HC; Timodine; Tinaderm-M; Tri-Adcortyl; Profile thyl)-3-furyl]methoxy}phenyl)-1-piperazinyl]phenyl}-1-[(1S,2S)- Tr imovate; USA: Myco-Biotic II; Myco-Triacet II; Mycogen II; Mycolog-II; My- Oxiconazole is an imidazole antifungal applied topically as the 1-ethyl-2-hydroxypropyl]-Δ2-1,2,4-triazolin-5-one. conel; Mytrex†; NGT; Tri-Statin II; Venez.: Halcicomb; Kenacomb. nitrate as a cream, solution, or powder equivalent to oxiconazole 1% in the treatment of fungal infections of the skin (p.521). It is Позаконазол also given as a pessary in a single dose equivalent to 600 mg of C37H42F2N8O4 = 700.8. oxiconazole in the treatment of vaginal candidiasis (p.518). CAS — 171228-49-2. Omoconazole Nitrate (USAN, rINNM) Local reactions including burning and itching have been report- ATC — J02AC04. ed. Intravaginal preparations of azoles may damage latex contra- ATC Vet — QJ02AC04. 10-80-07; Nitrato de omoconazol; Omoconazole, Nitrate d’; ceptives. Omoconazoli Nitras. (Z)-1-{2,4-Dichloro-β-[2-(p-chlorophe- For a discussion of the caution needed when using azole antifun- noxy)ethoxy]-α-methylstyryl}imidazole nitrate. gals during pregnancy, see under Pregnancy in Precautions of Fluconazole, p.532. Омоконазола Нитрат ◊ Reviews. C H Cl N O ,HNO = 486.7. 20 17 3 2 2 3 1. Jegasothy BV, Pakes GE. Oxiconazole nitrate: pharmacology, ef- CAS — 74512-12-2 (omoconazole); 83621-06-1 (omoco- ficacy, and safety of a new imidazole antifungal agent. Clin Ther nazole nitrate). 1991; 13: 126–41. Preparations ATC — D01AC13; G01AF16. Adverse Effects Proprietary Preparations (details are given in Part 3) ATC Vet — QD01AC13; QG01AF16. The most commonly reported adverse effects with Arg.: Oxistat; Austria: Gyno-Liderman; Liderman; Oceral; Braz.: Micotin; Oceral; Oxipelle; Oxitrat†; Canad.: Oxizole†; Cz.: Gyno-Myfungar†; My- posaconazole are headache and nausea. Other common fungar; Fr.: Fonx; Ger.: Myfungar; Oceral GB†; Mex.: Gyno-Myfungar†; adverse effects include abdominal pain, anorexia, Myfungar; Oxistat; Rus.: Myfungar (Мифунгар); Spain: Salongo; Switz.: Cl Oceral; Turk.: Oceral; USA: Oxistat. asthenia, back pain, diarrhoea, dyspepsia, dizziness, dry mouth, dry skin, fatigue, fever, flatulence, hot Multi-ingredient: India: Zoderm. flushes, insomnia, neutropenia, paraesthesia, pruritus, rash, somnolence, and vomiting. An increase in liver Cl enzyme values has occurred in some patients, especial- Parconazole Hydrochloride (USAN, rINNM) ly in those with serious underlying disease. Hypersen- H3C C O sitivity and allergic reactions, including Stevens-John- CO Hidrocloruro de parconazol; Parconazole, Chlorhydrate de; Par- son syndrome, have occurred rarely. N conazoli Hydrochloridum; R-39500. cis-1-{[2-(2,4-Dichlorophe- Cl nyl)-4-[(2-propynyloxy)methyl]-1,3-dioxolan-2-yl]methyl}-1H- imidazole hydrochloride. Precautions N Some azoles have been associated with QT interval Парконазола Гидрохлорид prolongation and licensed product information there- (omoconazole) C17H16Cl2N2O3. HCl = 403.7. fore advises that posaconazole should be used with CAS — 61400-59-7 (parconazole); 68685-54-1 (parco- caution in patients with potentially proarrhythmic con- nazole); 62973-77-7 (parconazole hydrochloride). ditions. Patients who develop abnormal liver function Profile Omoconazole is an imidazole antifungal used locally for fungal tests while being treated with posaconazole should be routinely monitored for the development of more seri- skin infections (p.521) and for vaginal candidiasis (p.518). It is Cl applied topically as the nitrate as a 1% cream, powder, or solu- ous liver injury. O tion in the treatment of cutaneous candidiasis, dermatophytosis, Breast feeding. Breast feeding while taking posaconazole is and pityriasis versicolor. For vaginal candidiasis, omoconazole O Cl HC not recommended by licensed product information. nitrate is given as pessaries in doses of 150 mg daily for 6 days, H O 300 mg daily for 3 days, or 900 mg as a single dose. Pregnancy. Posaconazole has been shown to be teratogenic and N embryotoxic in animal studies and its use is generally not recom- Intravaginal preparations of azoles may damage latex contracep- and enantiomer mended during pregnancy. For a discussion of the caution need- tives. ed when using azole antifungals during pregnancy, see under N Pregnancy in Precautions of Fluconazole, p.532. Licensed prod- For a discussion of the caution needed when using azole antifun- uct information recommends that women of child-bearing poten- gals during pregnancy, see under Pregnancy in Precautions of (parconazole) tial should use effective contraception during treatment with Fluconazole, p.532. posaconazole..
Load more

Recommended publications
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Lamisil Versus Clotrimazole in the Treatment of Vulvovaginal Candidiasis
    Volume 5 Number 1 (March 2013) 86-90 Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis Ali Zarei Mahmoudabadi1,2, Mahin Najafyan3, Eskandar Moghimipour4, Maryam Alwanian1, Zahra Seifi1 1Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 2Infectious Diseases and Tropical Medicine Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 3Department of Obstetric and Genecology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 4Department of Pharmaceutics, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Received: March 2012, Accepted: October 2012. ABSTRACT Background and Objectives: Vaginal candidiasis is a common disease in women during their lifetime and occurs in diabetes patients, during pregnancy and oral contraceptives users. Although several antifungals are routinely used for treatment; however, vaginal candidiasis is a challenge for patients and gynecologists. The aim of the present study was to evaluate terbinafine (Lamisil) on Candida vaginitis versus clotrimazole. Materials and Methods: In the present study women suspected to have vulvovaginal candidiasis were sampled and disease confirmed using direct smear and culture examination from vaginal discharge. Then, patients were randomly divided into two groups, the first group (32 cases) was treated with clotrimazole and the next (25 cases) with Lamisil. All patients were followed-up to three weeks of treatment and therapeutic effects of both antifungal were compared. Results: Our results shows that 12 (37.5%) patients were completely treated with clotrimazole during two weeks and, 6(18.8%) patients did not respond to drugs and were refereed for fluconazole therapy. Fourteen (43.8%) patients showed moderate response and clotrimazole therapy was extended for one more week.
    [Show full text]
  • Dermatologic Medication in Pregnancy
    Marušić et al. Acta Dermatovenerol Croat Subcutaneous dirofilariasis Acta Dermatovenerol Croat 2009;17(1):40-47 REVIEW Dermatologic Medication in Pregnancy Petra Turčić1, Zrinka Bukvić Mokos2, Ružica Jurakić Tončić2, Vladimir Blagaić3, Jasna Lipozenčić2 1School of Pharmacy and Biochemistry, University of Zagreb; 2University Department of Dermatology and Venereology, Zagreb University Hospital Center and School of Medicine; 3University Department of Obstetrics and Gynecology, Sveti Duh General Hospital, Zagreb, Croatia Corresponding author: SUMMARY In female body, a vast number of skin changes occur Petra Turčić, Phar. M. during pregnancy. Some of them are quite distressing to many women. Department of Pharmacology Therefore, performing treatment for physiologic skin changes during pregnancy with antiinfective agents, glucocorticosteroids, topical School of Pharmacy and Biochemistry immunomodulators, retinoids, minoxidil, etc., is discussed. Drug University of Zagreb administration during pregnancy must be reasonable. Domagojeva 2 KEY WORDS: dermatologic medication, pregnancy, physiologic skin HR-10000 Zagreb changes, treatment Croatia [email protected] Received: September 1, 2008 Accepted: January 9, 2009 INTRODUCTION In female body, a vast number of changes oc- bolic imbalances (3), diabetes and cardiovascular cur during pregnancy. Some of them are quite diseases (4). Pregnancy extends and alters the distressing to many women. Therefore, perform- impact of sex differences on absorption, distribu- ing treatment for these changes during pregnancy tion, metabolism and elimination (5). Cardiac out- is discussed. Normal pregnancy needs to avoid put is elevated early and remains elevated for the harmful drugs, both prescribed and over-the coun- remainder of pregnancy. Regional blood flow can ter, and drugs of abuse, including cigarettes, alco- change, with some areas of the skin having sub- hol as well as occupational and environmental ex- stantial increases in blood flow during the course posure to potentially harmful chemicals.
    [Show full text]
  • Safety, Tolerability and Pharmacokinetics of Intravaginal Pentamycin
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by edoc Pharmacology Chemotherapy 2010;56:190–196 Received: March 20, 2009 DOI: 10.1159/000316329 Accepted after revision: January 12, 2010 Published online: June 10, 2010 Safety, Tolerability and Pharmacokinetics of Intravaginal Pentamycin a a c b B. Frey Tirri J. Bitzer B. Geudelin J. Drewe a b Departments of Obstetrics and Gynecology, and Clinical Pharmacology, University Hospital Basel, and c Mediante GmbH, Basel , Switzerland Key Words cin does not cause adverse reactions compared with vehicle -Antimicrobial agents ؒ Pentamycin ؒ Pharmacokinetics ؒ and is not absorbed through the intact or the inflamed va Polyene antifungal antibiotic ؒ Vaginal infections gina. Copyright © 2010 S. Karger AG, Basel Abstract Background/Aims: Intravaginal pentamycin is a polyene Introduction macrolide with a broad spectrum of antimicrobial activity and is effective in various forms of infectious vaginitis. We The most common vaginal disorders include vaginal evaluated the safety, tolerability and pharmacokinetics of candidiasis, vaginal trichomoniasis and bacterial vagino- escalating doses of this product. Methods: Nineteen healthy sis [1–5] . Forms of infectious vaginitis sustained by mixed volunteers were randomized to receive double blind one of micro-organisms are also observed frequently [6] . Vagi- five doses of intravaginal pentamycin (3, 10, 30, 60 or 100 mg) nal infections can be successfully treated by using one or or the corresponding dose of pentamycin vehicle daily for more pathogen-specific antimicrobials [1, 3, 7–9] , but, be- 6 days. Patients with symptomatic vaginitis received a single fore vaginitis is treated, the cause must be ascertained by dose of 60 (n = 6) or 100 mg (n = 6) of intravaginal penta- using appropriate laboratory tests [1, 2, 6, 7, 10] .
    [Show full text]
  • United States Patent 19 [11] 3,957,754 Aszalos Et Al
    United States Patent 19 [11] 3,957,754 ASzalos et al. (45) May 18, 1976 54 COMPLEXES OF ANTIFUNGAL POLYENE 3,777,018 12/1973 Gordon et al................ 260/210 AB ANTIBOTCS FOREIGN PATENTS OR APPLICATIONS (75) Inventors: Adorjan Aszalos, Princeton; John Vandeputte, Milltown, both of N.J. 795,482 5/1958 United Kingdom.......... 260/210 AB (73) Assignee: E. R. Squibb & Sons, Inc., OTHER PUBLICATIONS Princeton, N.J. 22 Filed: Jan. 13, 1975 Mazor et al. “Chem. Abst." Vol. 57, 1962, p. 956g. 21 Appl. No.: 540,750 Primary Examiner-Johnnie R. Brown Related U.S. Application Data Attorney, Agent, or Firm-Lawrence S. Levinson; 62 Division of Ser. No. 100,492, Dec. 21, 1970, Pat. No. Merle J. Smith; Stephen B. Davis 3,879,374. 52 U.S. Cl........................... 260/210 AB; 424/180; 57) ABSTRACT 424/181 51 int. Cl'.......................................... C07H 15/20 Disclosed herein are complexes of polyene antibiotics 58 Field of Search.............. 260/210 AB; 424/117, which are soluble in alcohol or in water and alcohol. 424/119 These complexes are prepared in alcoholic solutions and have been found to be useful as antifungal agents 56) References Cited which can be orally administered. UNITED STATES PATENTS 6 Claims, No Drawings 2,865,807 12, 1958 Dutcher et al............... 260/20 AB 3,957,754 2 Alcohols that can be utilized to carry out the reaction COMPLEXES OF ANTIFUNGAL POLYENE are the lower alkyl alcohols of from 1 to 6 carbons such ANTBIOTICS as methanol, ethanol, isopropanol, isobutanol, butanol, This is a division of Ser.
    [Show full text]
  • Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm)
    Editorial | Journal of Gandaki Medical College-Nepal Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm) Reddy KR Professor & Head Microbiology Department Gandaki Medical College & Teaching Hospital, Pokhara, Nepal Medical Mycology, a study of fungal epidemiology, ecology, pathogenesis, diagnosis, prevention and treatment in human beings, is a newly recognized discipline of biomedical sciences, advancing rapidly. Earlier, the fungi were believed to be mere contaminants, commensals or nonpathogenic agents but now these are commonly recognized as medically relevant organisms causing potentially fatal diseases. The discipline of medical mycology attained recognition as an independent medical speciality in the world sciences in 1910 when French dermatologist Journal of Raymond Jacques Adrien Sabouraud (1864 - 1936) published his seminal treatise Les Teignes. This monumental work was a comprehensive account of most of then GANDAKI known dermatophytes, which is still being referred by the mycologists. Thus he MEDICAL referred as the “Father of Medical Mycology”. COLLEGE- has laid down the foundation of the field of Medical Mycology. He has been aptly There are significant developments in treatment modalities of fungal infections NEPAL antifungal agent available. Nystatin was discovered in 1951 and subsequently and we have achieved new prospects. However, till 1950s there was no specific (J-GMC-N) amphotericin B was introduced in 1957 and was sanctioned for treatment of human beings. In the 1970s, the field was dominated by the azole derivatives. J-GMC-N | Volume 10 | Issue 01 developed to treat fungal infections. By the end of the 20th century, the fungi have Now this is the most active field of interest, where potential drugs are being January-June 2017 been reported to be developing drug resistance, especially among yeasts.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • (Oral and Vaginal) Therapy for Recurrent Vulvovaginal Candidiasis: a Systematic Review Protocol
    Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2018-027489 on 22 May 2019. Downloaded from Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol Juliana Lírio,1 Paulo Cesar Giraldo,2 Rose Luce Amaral,2 Ayane Cristine Alves Sarmento,3 Ana Paula Ferreira Costa,3 Ana Katherine Gonçalves3 To cite: Lírio J, Giraldo PC, ABSTRACT Strengths and limitations of this study Amaral RL, et al. Antifungal Introduction Vulvovaginal candidiasis (VVC) is frequent (oral and vaginal) therapy in women worldwide and usually responds rapidly to for recurrent vulvovaginal ► Two independent reviewers will select studies, ex- topical or oral antifungal therapy. However, some women candidiasis: a systematic tract data without different variables and assess develop recurrent vulvovaginal candidiasis (RVVC), which review protocol. BMJ Open the risk of bias, to indicate through evidence-based 2019;9:e027489. doi:10.1136/ is arbitrarily defined as four or more episodes every medicine if there is a more effective antifungal ther- bmjopen-2018-027489 year. RVVC is a debilitating, long-term condition that can apeutic regimen for the treatment of recurrent vul- severely affect the quality of life of women. Most VVC is Prepublication history for vovaginal candidiasis. ► diagnosed and treated empirically and women frequently this paper is available online. ► There may be a limitation of outcome from treat- To view these files, please visit self-treat with over-the-counter medications that could ment variation, routes of administration, different the journal online (http:// dx. doi. contribute to an increase in the antifungal resistance. The doses and quality of the randomised trials used in org/ 10.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Diccionario Del Sistema De Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS
    DIRECCION GENERAL DE MEDICAMENTOS, INSUMOS Y DROGAS - DIGEMID EQUIPO DE ASESORIA - AREA DE CATALOGACION Diccionario del Sistema de Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS CODIGO DESCRIPCION ATC EN CASTELLANO DESCRIPCION ATC EN INGLES FUENTE A TRACTO ALIMENTARIO Y METABOLISMO ALIMENTARY TRACT AND METABOLISM ATC OMS A01 PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01A PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01AA Agentes para la profilaxis de las caries Caries prophylactic agents ATC OMS A01AA01 Fluoruro de sodio Sodium fluoride ATC OMS A01AA02 Monofluorfosfato de sodio Sodium monofluorophosphate ATC OMS A01AA03 Olaflur Olaflur ATC OMS A01AA04 Fluoruro de estaño Stannous fluoride ATC OMS A01AA30 Combinaciones Combinations ATC OMS A01AA51 Fluoruro de sodio, combinaciones Sodium fluoride, combinations ATC OMS A01AB Antiinfecciosos y antisépticos para el tratamiento oral local Antiinfectives and antiseptics for local oral treatment ATC OMS A01AB02 Peróxido de hidrógeno Hydrogen peroxide ATC OMS A01AB03 Clorhexidina Chlorhexidine ATC OMS A01AB04 Amfotericina B Amphotericin B ATC OMS A01AB05 Polinoxilina Polynoxylin ATC OMS A01AB06 Domifeno Domiphen ATC OMS A01AB07 Oxiquinolina Oxyquinoline ATC OMS A01AB08 Neomicina Neomycin ATC OMS A01AB09 Miconazol Miconazole ATC OMS A01AB10 Natamicina Natamycin ATC OMS A01AB11 Varios Various ATC OMS A01AB12 Hexetidina Hexetidine ATC OMS A01AB13 Tetraciclina Tetracycline ATC OMS A01AB14 Cloruro de benzoxonio
    [Show full text]
  • THI TOETATUTUMUTUALNIHUS009962372B2 (12 ) United States Patent ( 10 ) Patent No
    THI TOETATUTUMUTUALNIHUS009962372B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 , 962, 372 B2 Milanese et al. (45 ) Date of Patent: May 8 , 2018 ( 54 ) PHARMACEUTICAL COMPOSITION FOR ( 56 ) References Cited THE TREATMENT OF MYCOSIS U . S . PATENT DOCUMENTS (71 ) Applicant: AZIENDE CHIMICHE RIUNITE 2004 / 0180965 A1 * 9/ 2004 Borgman . .. .. A61K 9 /0034 ANGELINI FRANCESCO A . C . R . A . F . 514 /649 S . p . A ., Rome ( IT ) 2009/ 0208558 AL 8 / 2009 Noe et al . ( 72 ) Inventors : Claudio Milanese , Rome ( IT ) ; FOREIGN PATENT DOCUMENTS Alessandra Capezzone De Joannon , Rome ( IT ) ; Serena Tongiani, Genzano WO 96 / 26724 AL 9 / 1996 di Roma (IT ) ; Luca Donati , Porto San Giorgio ( IT ) OTHER PUBLICATIONS Rani et al. Mini- reviews in Medicinal chemistry, 2013 , 13 ( 11) , @( 73 ) Assignee : AZIENDE CHIMICHE RIUNITE 1626 - 1655 (abstract ) .* ANGELINI FRANCESCO A . C . R . A . F . Yucesoy et al. , “ In -vitro Synergistic Effect of Fluconazole with S . p . A . , Rome (IT ) Nonsteroidal Anti - Inflammatory Agents Against Candida albicans Strains” , Journal of Chemotherapy, vol. 12 , No . 5 , 2000 , p . 385 - 389 , XP 002429141 . @( * ) Notice : Subject to any disclaimer, the term of this Boselli et al . , “ Efficacy and Tolerability of Fitostimoline ( Vaginal patent is extended or adjusted under 35 Cream , Ovules , and Vaginal Washing ) and of Benzydamine Hydro U . S . C . 154 (b ) by 0 days . days . chloride ( Tantum Rosa Vaginal Cream and Vaginal Washing ) in the Topical Treatment of Symptoms of Bacterial Vaginosis ” , ISRN Obstetrics and Gynecology, vol. 2012 , 2012 , p . 1 - 5 . (21 ) Appl . No. : 15 /541 , 245 EUCAST, “ EUCAST Definitive Document EDef 7 . 1 : method for @I the determination of broth dilution MICs of antifungal agents for ( 22 ) PCT Filed : Jan .
    [Show full text]